Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations
暂无分享,去创建一个
B. Konkle | Tetsuji Sato | T. Matsushita | K. Nogami | M. Taki | M. Shima | B. Abbuehl | K. Fukutake | S. Higasa | W. Engl | M. Arai | M. Sakai | T. Fujii | Haruhiko Uchikawa
[1] P. Turecek,et al. Safety of PEGylated recombinant human full‐length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.
[2] B. Konkle,et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.
[3] L. Valentino,et al. The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.
[4] M. Ozelo,et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] J. Mahlangu,et al. Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] H. Ehrlich,et al. BAX 855, a PEGylated rFVIII product with prolonged half-life , 2011, Hämostaseologie.
[7] S. Jönsson,et al. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years , 2009, European Journal of Clinical Pharmacology.
[8] J. Stockman. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .
[9] A. Shapiro,et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin‐free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A 1 , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[10] J. Lusher,et al. The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.
[11] S. Björkman. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[12] E. Berntorp,et al. Pharmacokinetics of Coagulation Factors , 2001, Clinical pharmacokinetics.
[13] H. Brackmann,et al. Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy , 2000, Thrombosis and Haemostasis.
[14] H. Brackmann,et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy--International Kogenate-FS Study Group. , 2000, Thrombosis and haemostasis.
[15] E. Gomperts,et al. A Multicenter Study of Recombinant Factor VIII (RecombinateTM) in Previously Treated Patients with Hemophilia A , 1997, Thrombosis and Haemostasis.
[16] E. Gomperts,et al. A multicenter study of recombinant factor VIII (Recombinate(TM)) in previously treated patients with hemophilia A , 1997 .
[17] P. Mannucci,et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. , 1990, The New England journal of medicine.